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Abstract 
Astrocytes are responsible for the majority of the clearance of extracellular glutamate 
released during neuronal activity. DL-threo-β-benzyloxyaspartate (TBOA) is 
extensively used as inhibitor of glutamate transport activity, but suffers from relatively 
low affinity for the transporter. Here, we characterized the effects of (2S, 3S)-3-[3-[4-
(trifluoromethyl)benzoylamino]benzyloxy]aspartate (TFB-TBOA), a recently 
developed inhibitor of the glutamate transporter on mouse cortical astrocytes in 
primary culture. The glial Na+-glutamate transport system is very efficient and its 
activation by glutamate causes rapid intracellular Na+ concentration (Na+i) changes 
that enable real time monitoring of transporter activity. Na+i was monitored by 
fluorescence microscopy in single astrocytes using the fluorescent Na+-sensitive 
probe sodium-binding benzofuran isophtalate. When applied alone, TFB-TBOA, at a 
concentration of 1 µM, caused small alterations of Na+i. TFB-TBOA inhibited the Na+i 
response evoked by 200 µM glutamate in a concentration-dependent manner with 
IC50 value of 43±9 nM, as measured on the amplitude of the Na+i response. The 
maximum inhibition of glutamate-evoked Na+i increase by TFB-TBOA was >80%, but 
was only partly reversible. The residual response persisted in the presence of the 
AMPA/kainate receptor antagonist CNQX. TFB-TBOA also efficiently inhibited Na+i 
elevations caused by the application of D-aspartate, a transporter substrate that does 
not activate non-NMDA ionotropic receptors. TFB-TBOA was found not to influence 
the membrane properties of cultured cortical neurons recorded in whole-cell patch 
clamp. Thus, TFB-TBOA, with its high potency and its apparent lack of neuronal 
effects, appears to be one of the most useful pharmacological tools available so far 
for studying glial glutamate transporters. 
 
Section: 3. Neurophysiology, Neuropharmacology and other forms of Intercellular 
Communication. 
 
Keywords: astrocytes; neurons; glutamate transport inhibition; TBOA; TFB-TBOA, 
intracellular sodium concentration; ion homeostasis; EAAT 
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1. Introduction 
By rapidly taking up extracellular glutamate, astroglial cells play the critical role of 
protecting neurons from the excitotoxic buildup of glutamate, thereby ensuring the 
fidelity of glutamatergic transmission at high frequency (Danbolt, 2001). Astrocytic 
glutamate uptake also plays an important role in the coupling between synaptic 
activity and glucose utilization, i.e. neurometabolic coupling (Pellerin et al., 2007). 
Astrocytes are equipped with efficient glutamate transporters that surround the 
synaptic cleft and use the electrochemical gradient of Na+ to take up glutamate 
against its electrochemical gradient. In these cells, the Na+-coupled glutamate 
transport system is so efficient that the astrocytic intracellular Na+ concentration 
(Na+i), undergoes rapid and large elevations when glutamate is applied 
extracellularly, even at low micromolar concentration (Chatton et al., 2000).The bulk 
of glutamate uptake in the adult brain is mediated by astroglia that express mostly 
the excitatory amino acid transporter (EAAT) isoforms 1 and 2, whereas EAAT3 and 
EAAT4 are considered to be neuronal transporters, and EAAT5 is retina-specific 
(Danbolt, 2001). 
Inhibitors of Na+-dependent glutamate transporters are therefore invaluable tools 
for elucidating the physiological roles of these transporters in detail. Earlier inhibitors 
of glutamate transporters, such as threo-β-hydroxyaspartate (THA) and trans-
pyrrolidine-2,4-dicarboxylic acid (t-PDC), are transported competitive inhibitors that 
lead to astrocytic coupled Na+ influx (Chatton et al., 2001). A more recently 
synthesized compound, DL-threo-β-benzyloxyaspartate (TBOA) has been introduced 
and since then widely used as a non-transported competitive inhibitor of glutamate 
transporters (Shimamoto et al., 1998). This compound is a non-selective inhibitor of 
all EAATs subtypes with activity in the micromolar range. While this compound was a 
real breakthrough for the study of glutamate transport, its relatively low potency 
imposes the use of fairly high concentrations, increasing the risk of unwanted effects 
in particular when used in situ (Bernardinelli and Chatton, 2008), or when in vivo use 
is envisaged for instance as a possible treatment for mood disorder pathologies (Lee 
et al., 2007; Sanacora et al., 2003). 
Recently, a series of analogues of TBOA have been reported with both improved 
potency and selectivity (Shimamoto et al., 2004). Among them, the most promising 
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one appears to be TFB-TBOA with nanomolar affinity for EAATs. In the present 
study, we characterized the effects of TFB-TBOA on the Na+i response to glutamate 
in primary mouse astrocytes and on the electrical properties of pure cortical neurons 
in primary culture. 
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 2. Results  
Glutamate evokes a robust elevation of Na+i in mouse astrocytes in primary culture 
(Chatton et al., 2000) that is primarily due to Na+/glutamate cotransport activity. The 
first set of experiments was aimed at determining whether the new inhibitor of the 
glutamate transporter TFB-TBOA applied alone influenced baseline Na+i levels and at 
characterizing its inhibitory properties on the Na+i responses to glutamate application. 
Fig. 1A shows an original experimental trace of the Na+i response to 200 µM 
glutamate superfusion in a single astrocyte. In these experiments, Na+i went from a 
typical resting value of 12 mM to 33 mM. The baseline Na+i as well as the amplitude 
and kinetics of the response to glutamate in this series of experiments corresponds 
to what was described in previous studies (Chatton et al., 2000). 
TFB-TBOA 1 µM was then applied alone leading to a small change in Na+i. When 
co-applied with glutamate, TFB-TBOA inhibited 83±1% of the glutamate response. 
After washout of TFB-TBOA, the Na+i response to glutamate was restored however, 
with a slower kinetics and lower amplitude. Fig. 1B summarizes the results obtained 
in this series of experiments. 
An inhibition curve of TFB-TBOA on the astrocytes response to 200 µM glutamate 
was then established (Fig. 2). The graph shows that TFB-TBOA inhibited the Na+i 
response with high affinity, with an apparent IC50 of 43±9 nM when measured on the 
maximal amplitude of the response. In the presence of this maximally effective 
concentration of TFB-TBOA, about 17% of the Na+i response to glutamate subsisted 
(Figs. 1 and 2). We thus tested whether this residual response was due to 
AMPA/kainate receptor activation, which also leads to Na+i increase in astrocytes  
(Chatton et al., 2000) rather than to incomplete transporter blockade. Fig. 3 indicates 
that co-application of TFB-TBOA and CNQX did not further inhibit the Na+i response 
to 200 µM glutamate. 
As seen in Fig. 1, TFB-TBOA caused a small Na+i response in the absence of 
glutamate. We thus tested for the potential involvement of three major classes of 
astrocytic receptors in this response. Fig. 3 shows that addition of the AMPA/kainate 
receptor antagonist CNQX (50 µM) did not abolish the Na+i change caused by 1 µM 
TFB-TBOA. Application of the metabotropic glutamate receptor antagonist (S)-α-
Methyl-4-carboxyphenylglycine (MCPG, 1mM) or the P2 purinergic receptor 
Brain Research (2010) 1316:27-34 
 6 
antagonist suramin (100 µM) did not influence the response to TFB-TBOA alone, 
excluding the contribution of these classes of receptors. 
In order to have a more direct assessment of the ability of TFB-TBOA to interfere 
with transport activity, we tested D-aspartate, a substrate of the glutamate transporter 
that is not metabolized nor activates ionotropic receptors. TFB-TBOA inhibited ~90% 
of the Na+i response to 200 µM D-aspartate in astrocytes (Fig. 4). The reversibility of 
the inhibition on the response to D-aspartate was of 60±2%, i.e. somewhat lower 
than was observed with glutamate (see Fig. 1).  
We then tested whether the incomplete reversibility of the response to glutamate 
after TFB-TBOA washout was persistent with time. Fig. 5 indicates that the 
reversibility improved with time, without however being complete 1 hour after 
washout of the compound. Interestingly, both the amplitude and the initial rate of Na+i 
rise recovered with a similar timecourse. 
In order to investigate the mode of action of TFB-TBOA, a Schild analysis was 
performed (Fig. 6). The Na+i responses to application of glutamate at different 
concentrations were measured in the absence or in the presence of TFB-TBOA 
applied at 10, 50 and 100 nM. From a family of three-point dose-response curves, 
the apparent EC50 of glutamate was estimated and used to build the Schild plot (Fig. 
6B), which yielded a linear slope of 1.6 (R2=0.96), different from unity and thus not 
compatible with pure competitive antagonism. 
Finally, we investigated the effect of TFB-TBOA on the membrane properties of 
cortical neurons in pure primary cultures. Neurons were recorded in whole-cell patch 
clamp in voltage-clamp configuration and the current-to-voltage relationship was 
analyzed in the presence and in the absence of 1 µM TFB-TBOA. Current-voltage 
plot shown in Fig. 7 shows that the resting membrane potential was -80 mV 
regardless of the presence or absence of TFB-TBOA and that the inhibitor did not 
influence the input resistance. In some recorded neurons, spontaneous or network-
induced firing of action potentials was observed and did not appear to be influenced 
by the presence of TFB-TBOA (not shown).  
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3. Discussion 
The aim of this report was to characterize the effects of the new glutamate 
transporter inhibitor TFB-TBOA on astrocytes in primary culture. As astrocytes are 
equipped with a high density of Na+-coupled glutamate transporter, Na+i 
concentration undergoes rapid and robust increases in these cells, which can be 
measured by microspectrofluorimetric methods (see e.g. Chatton et al., 2000; Rose 
et al., 1997). This Na+i increase is almost entirely attributable to the activity of the 
Na+-glutamate cotransporters. Glial glutamate transporters use a complex 
stoichiometry of 3 Na+ plus 1 H+ cotransported (or 1 OH- exchanged) with 1 
glutamate and exchanged against 1 K+ (Levy et al., 1998). As the transport cycle is 
electrogenic, glutamate transport leads to a net inward current that can be measured 
by electrophysiological means. Transport activity can also be measured by 
radioactive tracers of transporter substrates, e.g. glutamate or D-aspartate. 
Measuring Na+i changes, as performed in the present study, offers the advantages of 
assessing transport activity in real time and at the single cell level.  
The first non-transported inhibitors of glutamate transporters were dihydrokainate, 
with selectivity for EAAT2 (GLT-1), and more recently TBOA, acting on all EAAT 
subtypes. Both compounds have been widely used but suffer from a relatively low 
affinity on glutamate transporters and are accompanied with complex unwanted 
effects (Bernardinelli and Chatton, 2008). The newly released compound TFB-TBOA 
offers the promise of a high potency of inhibition in the nanomolar range. 
The original report characterizing TFB-TBOA (Shimamoto et al., 2004) described 
the inhibition glutamate transport measured by 14C-glutamate uptake in COS cells 
expressing EAATs or measured by transporter currents in Xenopus laevis oocytes 
expressing EAATs. The reported IC50 vales were 22, 17 and 300 nM for EAAT1, 
EAAT2, and EAAT3, respectively.  
In the present study TFB-TBOA was tested on mouse astrocytes. The only 
glutamate transporter functionally expressed in primary mouse astrocytes is the 
EAAT1 (GLAST) subtype, as the GLT-1 inhibitor dihydrokainate fails to inhibit the 
Na+i response to glutamate (Chatton et al., 2001). We found that TFB-TBOA inhibited 
Na+i responses evoked by 200 µM glutamate in a concentration-dependent manner 
with an apparent IC50 of 43 nM. Previous measurements of inhibition of synaptically 
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activated transporter currents in astrocytes in the hippocampus yielded an IC50 value 
of 13 nM (Tsukada et al., 2005). We found a maximal inhibition of ~80% on the Na+i 
response to glutamate, whereas the inhibition was more pronounced (~90%) when 
D-aspartate was used as a transport substrate. 
TFB-TBOA showed however incomplete reversibility of inhibition. Whereas the 
amplitude of the Na+i responses to glutamate measured 5 minutes after washout of 
the compound was overall 69% of the original amplitude, the rise-time was 
significantly slower (~4-fold), possibly because some fraction of the compound 
remains bound because of its high affinity for the transporter. It is plausible that TFB-
TBOA does not only act as a pure competitive inhibitor of transport, but also displays 
some non-competitive component. Schild analysis of the inhibition of glutamate-
mediated Na+i responses by TFB-TBOA indeed supported this conclusion. In 
addition, we observed that reversibility of responses was gradually improving with 
time after washout of the drug. This result is consistent with observations made on 
EAAT transporter currents measured in oocytes (Shimamoto et al., 2004), for which 
the recovery was incomplete even 1 hour after washout of TFB-TBOA. We found that 
not only did the amplitude gradually recovered, but also the initial rate of Na+i rise 
with a similar timecourse. Our previous mathematical modeling of the Na+i response 
to glutamate has shown that this parameter best reflects the kinetics properties of the 
transporter (Chatton et al., 2000). This indicates that TFB-TBOA causes an alteration 
of transporter function, which persists after washout of the drug. This incomplete 
reversibility of inhibition is a limitation for the use of TFB-TBOA that has to be taken 
into account in experimental designs. 
Whereas TFB-TBOA applied alone was shown not to elicit detectable currents in 
oocytes expressing glutamate transporters (Shimamoto et al., 2004), we found, 
however, that in primary mouse astrocytes a small but significant Na+i increase was 
evoked by TFB-TBOA, as was found to be the case for TBOA (Chatton et al., 2001). 
As NMDA receptors are not found in cultured astrocytes (Verkhratsky and Kirchhoff, 
2007) and as the AMPA/kainate receptor antagonist CNQX did not prevent this Na+i 
increase, the mechanism of the TFB-TBOA evoked Na+i rise does not involve 
ionotropic glutamate receptors. Metabotropic glutamate and P2 purinergic receptors 
could also be excluded. Thus, this response to TFB-TBOA could be related to 
interference with other Na+ carrier proteins such as the Na,K-ATPase. The 
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observation would also be compatible with TFB-TBOA being a low efficacy 
transporter substrate, which could elicit a small Na+i response. 
 In previous studies performed under the same experimental conditions, we had 
found that the maximum inhibition caused by TBOA on the Na+i response to 200 µM 
glutamate was ~70% (Chatton et al., 2001). We show here that the maximal inhibition 
caused by TFB-TBOA on the response to glutamate was somewhat larger (>80%). 
As was found for TBOA, the TFB-TBOA-insensitive residual Na+i response to 
glutamate, was not mediated by non-NMDA receptors and it is currently unclear what 
pathways is responsible for this residual signal. By contrast, the EAAT transporter 
currents measured in oocytes were reported to be fully inhibited by TFB-TBOA 
(Shimamoto et al., 2004). 
It is generally accepted that astroglial cells in situ express mostly the EAAT2 
(GLT-1) subtype of transporter (Dunlop, 2006), whereas when studied in primary 
cultures, EAAT1 (GLAST) becomes the almost exclusively functional isoform 
expressed. As was the case with TBOA, TFB-TBOA has almost identical affinity for 
both isoforms of the transporter (Shimamoto et al., 2004). However, TFB-TBOA was 
reported to have an approximately 15-fold lower affinity for EAAT3, a mostly neuronal 
transporter isoform, which means that this compound could potentially be used to 
discriminate between the contribution of glial and neuronal glutamate transport in the 
intact tissue. In addition, we found that TFB-TBOA at its maximally effective 
concentration did not influence the passive membrane electrical properties of cortical 
neurons and apparently did not alter their excitability. 
Selective inhibition of the EAAT2 (GLT-1) subtype is classically achieved with 
dihydrokainate, which, however, possesses a fairly low affinity for the transporter 
(Bridges and Esslinger, 2005) and causes complex effects on astrocytes in situ 
(Bernardinelli and Chatton, 2008). A very recent report described the first selective 
inhibitor of EAAT1, UCPH-101, with an IC50 of ~1 µM and > 400-fold selectivity over 
EAAT2 and EAAT3 (Jensen et al., 2009). With TFB-TBOA acting on both glial 
isoforms, the latter pharmacological tool could represent an interesting complement 
for the functional studies of glutamate transport.  
Taken together, the present study showed that TFB-TBOA is able to inhibit Na+-
dependent glutamate transport in astrocytes with high potency. Despite a partial 
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reversibility of inhibitory effects that have to be taken into account in experimental 
designs, TFB-TBOA is to be considered as an extremely valuable tool to study 
glutamate transport and neuron-glia interactions. 
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4. Experimental Procedure 
4.1. Cell culture and solutions 
Every effort was made to minimize suffering and the number of animals used in all 
experiments. In addition, all the procedures used to prepare living cells have been 
approved by the Swiss legislation and follows their guidelines. Primary cultures of 
mouse astrocytes were prepared as previously described (Chatton et al., 2000). After 
microdissection of cortices from 1-4 days-old C57bl6 mice, tissue was mechanically 
dissociated by successive aspirations through sterile syringes. The isolated 
astrocytes were then plated on glass coverslips and cultured in DME medium 
(D7777, Sigma, Buchs, Switzerland) supplemented with 10% FCS penicillin, 
streptomycin and amphotericin. Astrocytes were used after 2-3 weeks of culture. 
Mouse cortical neurons in primary cultures were obtained from 17-days C57bl6 
mouse embryos. After removing meninges, entire cortices were first incubated with 
20 U/ml papain for 30 min at 34°C and then mechanically dissociated in MEM 
medium plus glucose, glutamine and 10% FCS, by successive aspiration through 
sterile plastic 2 ml pipettes. The dissociated cells were centrifuged at 1300 rpm for 2 
minutes and then re-suspended at a density of 80-85,0000 cells per cm2 in 
Neurobasal (Invitrogen, Basel, Switzerland) culture medium complemented with 2% 
B27 solution (Invitrogen), 500 µM glutamine according to Brewer et al. (Brewer et al., 
1993). Cells were then plated on glass coverslips coated with poly-L-Ornithine 
(Sigma, Buchs, Switzerland). Cells were used after 7-14 days of culture. 
Experimental solutions used during experiments with astrocytes and neurons 
contained (mM): NaCl 135, KCl 5.4, NaHCO3 25, CaCl2 1.3, MgSO4 0.8, NaH2PO4 
0.78, glucose 5, bubbled with 5% CO2/95% air.  
TBOA and TFB-TBOA were from Tocris-Anawa Trading (Zürich). Unless 
otherwise state, all other compounds were from Sigma. 
4.2 Na+i fluorescence imaging 
Na+i measurements were performed as previously described (Chatton et al., 2000). 
Briefly, experiments were carried out on the stage of an inverted epifluorescence 
microscope (Nikon, Tokyo, Japan) and observed through a 40x 1.3 N.A. oil-
Brain Research (2010) 1316:27-34 
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immersion objective lens (Nikon). Fluorescence excitation wavelengths were 
selected using fast filter wheel (Sutter Instr., Novato, CA) and fluorescence was 
detected using a Gen III+ intensified CCD camera (VideoScope Intl., Washington 
D.C.). Acquisition and digitization of video images, as well as time series was 
computer-controlled using the software Metafluor (Universal Imaging, West Chester, 
PA, USA) running on a Pentium computer. Four video frames were averaged at each 
wavelength and the acquisition rate of ratio images was varied between 0.5 Hz and 
0.1 Hz. Up to 10 individual astrocytes were simultaneously analyzed in the selected 
field of view. 
Na+i was measured in single cells grown on glass coverslips after loading the cells 
with the Na+-sensitive fluorescent dye sodium-binding benzofuran isophthalate 
(SBFI-AM, Teflabs, Austin, TX). Cell loading was performed at 37°C using 15 µM 
SBFI-AM in a HEPES-buffered balanced solution containing (mM): NaCl 160, KCl 
5.4, HEPES 20, CaCl2 1.3, MgSO4 0.8, NaH2PO4 0.78, glucose 20 and was 
supplemented with 0.1 % Pluronic F-127 (Molecular Probes, Eugene, OR). 
Once loaded with SBFI, cells were placed in a thermostated perfusion chamber 
designed for rapid exchange of perfusion solutions and superfused at 35°C. 
Fluorescence was sequentially excited at 340 nm and 380 nm and detected at 
>520 nm. Fluorescence excitation ratios (F340nm/F380nm) were computed for each 
image pixel and produced ratio-images of cells that were proportional with Na+i. In 
situ calibration was performed after each experiment by permeabilization of the cell 
membrane for monovalent cations using 6 µg/ml gramicidin and 10 µM monensin 
with simultaneous inhibition the Na+/K+-ATPase using 1 mM ouabain. Cells were then 
sequentially perfused with solutions buffered at pH 7.2 with 20 mM HEPES and 
containing 0, 10, 20 and 50 mM Na+, respectively, and 30 mM Cl-, 136 mM gluconate 
with a constant total concentration of Na+ and K+ of 165 mM. A four-point calibration 
curve was computed for each selected cell in the field of view and used to convert 
fluorescence ratio values (F340nm/F380nm) into Na+ concentrations. 
4.3. Whole-cell electrophysiological recordings in neurons 
Whole-cell voltage-clamp recordings were made with borosilicate glass pipettes with 
a resistance of 5.5-8 MΩ. In voltage-clamp mode, the clamp potential was set at -70 
mV. Recordings were made with an Axopatch 200A amplifier (Axon Instruments). 
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Current were filtered at 1 kHz. Data were acquired with a Digidata 1440A (Axon), at 
10 kHz sampling rate, controlled with Pclamp 10 software and analyzed with Clampfit 
software (Axon). A period of 5 min was routinely allowed after establishment of the 
whole-cell configuration. The patch-clamp intracellular solution contained (in mM): K-
gluconate 130, NaCl 5, Na-phosphocreatine 10, MgCl2 1, EGTA 0.02, HEPES 10, 
Mg-ATP 2, Na3-GTP 0.5, pH 7.3 (adjusted with KOH).  
Experiments were performed using an open perfusion chamber. Control 
extracellular solutions and solutions containing the tested drugs were gravity fed at 
600 µl/min and 35°C on the cultured cells. 
4.4. Data analysis 
Data are means ± SEM and are represented as percentage of the control current or 
voltage amplitude. Paired student t-tests or ANOVA tests were performed to assess 
the statistical significance (*, P<0.05; **, P≤0.01). The half-maximum inhibitory 
concentration (IC50) of TFB-TBOA on the response to glutamate was determined by 
non-linear curve fitting performed using the Levenberg-Marquardt algorithm 
implemented in the Kaleidagraph software package (Synergy Software, Reading, PA, 
USA). The dose-response analysis experiments were fitted using the following 
equation:  
 Robs = Rmax [I] / (K + [I]) + Rmin (1) 
where Robs, is the observed response, Rmax, Rmin are maximum and minimum 
parameters of the response. [I] is the concentration of the inhibitor compound and K 
the concentration that yields its half-maximum inhibition (i.e. IC50). 
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Figure legends 
 
Fig. 1 – Inhibition by TFB-TBOA of the glutamate-evoked Na+i response. (A) 
representative experimental trace depicting the Na+i increase caused by application 
of 200µM glutamate followed by the application of TFB-TBOA 1µM alone and 
subsequently applied with glutamate. A final application of glutamate shows the 
reversibility of the response. (B) TFB-TBOA effects on the glutamate-evoked Na+i 
response. Results are expressed as maximum amplitude of Na+i and presented as 
percent of those observed with 200 µM glutamate. Data are means ± SEM of 40 cells 
from 5 independent experiments.  
 
Fig. 2 – Concentration-dependency of the inhibitory effects of TFB-TBOA. Inhibitory 
curve on the maximum amplitude of Na+i response to 200 µM glutamate. Non-linear 
least square fits using 135 cells from 17 experiments yielded IC50 values of 43±9 nM. 
The maximum inhibition was observed at 1 µM TFB-TBOA. 
 
Fig. 3 – Residual Na+i increase in the presence of TFB-TBOA. The TFB-TBOA-
insensitive residual Na+i response to 200 µM glutamate was not altered by non-
NMDA receptor inhibitor CNQX (50 µM, means ± SEM of 40 cells from 5 independent 
experiments). The Na+i increases observed upon TFB-TBOA (1 µM) application 
alone were not abolished by non-NMDA receptor inhibitor CNQX (50 µM, 52 cells 
from 7 independent experiments), the metabotropic glutamate receptor antagonist 
MCPG (1 mM, 40 cells from 5 experiments), or the P2 purinergic receptor antagonist 
suramin (100 µM, 23 cells from 3 experiments). Results are expressed as maximum 
amplitude of Na+i and presented as percent of those observed with 200 µM glutamate 
used as a control. 
 
Fig. 4 – Inhibition by TFB-TBOA of the D-aspartate-evoked Na+i response. Results 
are expressed as maximum amplitude of Na+i and presented as percent of those 
observed with 200 µM D-aspartate. Data are means ± SEM of 56 cells from 7 
independent experiments. 
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Fig. 5 – Reversibility of TFB-TBOA inhibitory effects. The recovery of the response to 
200 µM glutamate was tested consecutively 5, 15, 30, 60 minutes after washout of 
TFB-TBOA (1 µM). Results are expressed as amplitude or initial rate of rise of Na+i 
responses and presented as percent of the response recorded for the first control 
application of 200 µM glutamate. The significance of recovery was tested against the 
initial control glutamate application. Data are means ± SEM of 46 cells from 6 
independent experiments. 
 
Fig. 6 – Schild analysis of inhibitory action of TFB-TBOA. (A) The Na+i responses to 
applications of glutamate at different concentrations were measured in the absence 
or in the presence of TFB-TBOA present at three different concentrations indicated in 
the graph. Data are means±SEM of 16-24 cells from 13 experiments. (B) Schild plot 
of the data in (A). Dose ratio is the ratio of the apparent EC50 of glutamate obtained 
from the family of three-point dose-response curves in (A) in the presence of a given 
concentration of TFB-TBOA over the EC50 of glutamate in the absence of TFB-
TBOA. The linear regression yielded a slope of 1.6 (R2=0.96). 
 
Fig. 7 – Effects of TFB-TBOA on the passive membrane properties of cultured 
cortical neurons in whole-cell configuration. (A) Representative whole-cell current 
responses of a neuron to 20 mV voltage steps (-140 mV to -60 mV, see inset). The 
cell was clamped at -70 mV and measurements were done with and without 1 µM 
TFB-TBOA. (B) Current-voltage relationship recorded in the absence and in the 
presence of TFB-TBOA, as well as after washout of the compound. Input resistances 
were not significantly different among groups. Data are means ± SEM from 9 
individually recorded neurons.  
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